Although the introduction of novel agents to the autologous transplant procedure in patients less than 65 years old or to the Melphalan Prednisone regimen in elderly patients has significantly improved response rates and survival times, MM is a heterogeneous disease with divergent outcomes driven by the biologic characteristics, especially cytogenetic characteristics [5, 6]. Various studies have demonstrated that cytogenetic characteristic as detected by fluorescent in situ hybridization (FISH) was one of the most powerful prognostic marker in MM, especially presence of deletion of 17p13 (del17p) [6, 7] and translocation t(4;14) [6, 7] that represent approximately 20% to 25% of patients in the series [8]. The del(17p) and t(4;14) chromosomal abnormalities are associated with poor progression-free survival and shorter overall survival in newly diagnosed MM patients treated with traditional chemotherapy … The conclusion of recent studies were that a clear unmet medical need still exists for additional novel therapeutic options for the treatment of MM with del17p and t(4;14) and that novel agents should be proposed earlier in the patient evolution.